Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary MethylGene Presents Clinical Data on Mocetinostat at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting View HTML
Toggle Summary MethylGene to Present at the Jefferies 2013 Healthcare Conference View HTML
Toggle Summary MethylGene to Present Mocetinostat Data at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting View HTML
Toggle Summary MethylGene Reports First Quarter 2013 Financial Results View HTML
Toggle Summary MethylGene Announces Plan to Reincorporate in the United States as Mirati Therapeutics, Inc. and List on the NASDAQ View HTML
Toggle Summary MethylGene Presents Preclinical Data on MGCD516 at the AACR
Novel Spectrum of Targets for Differentiated Pipeline Product
View HTML
Toggle Summary MethylGene Reports Results of Phase II Trial of MGCD290
Company Focused on Developing its Oncology Assets
View HTML
Toggle Summary MethylGene Announces Management Changes View HTML
Toggle Summary MethylGene Reports Fourth Quarter and Full Year 2012 Financial Results View HTML
Toggle Summary MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO View HTML